DocGo Posts 19% Ex-Migrant Growth as Shares Slip Below 0.50

DocGo Inc (DCGO) told investors on its Q2 2026 earnings call that revenue excluding its wound-down migrant services work grew 19% and medical transportation volumes hit a record, while margins came under pressure and the company folded in an acquisition of Hicuity; the shares traded at 0.46, down 2.57%, as of 13:46 GMT on 19 August 2026.

DocGo Inc (DCGO) used its second-quarter 2026 earnings call to make a single argument: the business that remains after its migrant services contracts wound down is growing, and growing fast. Management pointed to 19% revenue growth excluding migrant work and record volumes in medical transportation. The market was not persuaded on the day. The shares changed hands at 0.46, down 2.57% from the prior close of 0.48, as of 13:46 GMT on 19 August 2026, in a session where the broad market was higher — SPY up 0.38% at $770.39 and DIA up 0.33% at $534.69.

That gap between operating narrative and share price is the whole story here. DocGo is doing two hard things at once: replacing a large, unrepeatable revenue stream and integrating what it called a transformative acquisition, Hicuity, while its own margin line is under strain.

Why the Ex-Migrant Number Is the One That Counts

For a period, DocGo's reported revenue was dominated by government-funded migrant care and shelter services — high-dollar, low-visibility, politically exposed work with a defined end. Once that revenue rolls off, headline growth rates go negative even if the underlying company is expanding. That is why management is directing attention to the ex-migrant figure.

A 19% growth rate on that base, as reported in the GuruFocus summary of the call, is a respectable clip for a services business built on payer contracts and municipal relationships. The complication is credibility: investors have been asked before to look past a transition, and the burden of proof sits with a company whose shares trade below half a unit of currency. At that price level, the equity behaves less like a growth stock and more like an option on execution.

Record Transportation Volumes Are a Utilization Story, Not a Pricing One

Record medical transportation volumes matter because ambulance and non-emergency medical transport economics are dominated by fixed cost absorption. Vehicles, crews, dispatch and compliance overhead are largely committed; the marginal trip is what pays for them. More completed transports per available unit is the operating lever that turns a low-margin logistics business into a profitable one.

But volume records and margin pressure appearing in the same quarter tell you something specific: the incremental volume is not arriving at incremental prices high enough to offset cost inflation. In this sector the usual suspects are labor — paramedic and EMT wages, overtime to cover shifts — plus vehicle maintenance and fuel, and payer mix, where a heavier weighting toward lower-reimbursement contracts drags the average revenue per transport down even as trip counts climb. DocGo did not, on the facts available, put a number on which of those dominated. Investors should press for revenue per transport alongside the volume record.

What the Hicuity Deal Is Meant to Fix

The acquisition of Hicuity is being framed as transformative rather than incremental, which sets a high bar. Strategically, the logic of pairing a mobile-care and transport network with a remote clinical monitoring capability is straightforward: transport is asset-heavy and margin-thin, while monitoring and virtual clinical oversight are contract-based, scalable and typically carry a better gross margin profile. Adding the second to the first is one of the few credible ways for a company like DocGo to lift blended margins without simply raising prices on payers who are pushing back.

Integration is where the thesis gets tested. Acquisitions of this kind bring purchase accounting noise, transaction and retention costs, and a period in which reported EBITDA is harder to compare with prior quarters. That is consistent with a widened EBITDA guidance range — a wider band is a company telling the market it is less certain about the middle of the distribution, usually because a new asset, a new cost structure or both have just entered the model.

Reading a Widened Guidance Range

Guidance width is information. Narrowing a range signals confidence as a year progresses; widening it, particularly mid-year, signals the opposite or signals complexity. In DocGo's case the complexity is real and identifiable: a revenue base being rebuilt around organic contracts, a newly acquired business whose contribution has not yet been demonstrated over a full quarter under DocGo ownership, and cost pressure that has already shown up in margins.

For anyone underwriting the stock, the questions that follow from this quarter are concrete rather than philosophical:

How much of the 19% ex-migrant growth is organic versus acquired, and does that rate hold when the comparison base no longer flatters it?
Is revenue per medical transport rising, flat or falling against the record volume count?
What does Hicuity contribute to revenue and to EBITDA on a run-rate basis, and what does integration cost before it does?
Where does the balance sheet sit after funding the deal, and does the company need to return to markets at a share price this low?

The Price Tells You What the Market Believes

The trading action on 19 August is a small but honest datapoint. DCGO printed a day range of 0.46 to 0.50 and sat at the low end of it, roughly 8% below the session high on an illustrative basis, while the S&P 500 proxy and the Dow proxy were both up and QQQ was fractionally higher at $718.33. A stock that fades on a quarter featuring record volumes and a 19% growth statistic is a stock where the market is discounting the margin line and the integration risk more heavily than the top line.

That is not a verdict. Sub-1.00 healthcare services names with genuine contract growth do re-rate when EBITDA follows revenue and guidance narrows again. The bar DocGo has set for itself with the word transformative is that Hicuity shows up in reported profitability, not just in the strategic slide. The next two quarters, with the acquisition inside the numbers and the migrant comparison finally behind it, are where that gets settled.

Key facts

DCGO share price: 0.46, -2.57% on the day, as of 13:46 GMT 19 Aug 2026
Ex-migrant revenue growth: 19% in Q2 2026
Medical transportation volumes: Record level reported for the quarter
Acquisition: Hicuity, described by management as transformative; EBITDA guidance range widened

Frequently asked questions

What did DocGo report for the second quarter of 2026?

DocGo reported 19% revenue growth excluding its migrant services work and record medical transportation volumes for Q2 2026. Management also flagged margin pressure during the quarter and widened its EBITDA guidance range, and discussed the acquisition of Hicuity, which it characterized as a transformative deal for the company's service mix.

Why does DocGo report revenue excluding migrant services?

DocGo's migrant care and shelter contracts were large, government-funded and finite. As that work wound down, reported total revenue fell even where the underlying business grew. Excluding it isolates the continuing operations investors will own going forward, which is why management highlighted a 19% ex-migrant growth rate rather than a headline total.

How did DocGo shares react?

DCGO traded at 0.46 as of 13:46 GMT on 19 August 2026, down 2.57% from the prior close of 0.48, with an intraday range of 0.46 to 0.50. That decline came on a day when the S&P 500 proxy SPY was up 0.38%, the Dow proxy DIA up 0.33% and the Nasdaq 100 proxy QQQ up 0.11%.

What is Hicuity and why does the acquisition matter?

Hicuity is the business DocGo acquired and described as a transformative addition. The strategic rationale for pairing remote clinical monitoring with an asset-heavy transport and mobile-care network is margin mix: contract-based monitoring services typically carry better gross margins than ambulance trips, which depend on filling committed capacity.

Why did DocGo widen its EBITDA guidance range?

A wider range signals less certainty about the middle of the outcome distribution. In DocGo's case, two identifiable sources of uncertainty exist at once: a revenue base being rebuilt after migrant contracts ended, and a newly acquired business whose full-quarter contribution and integration costs have not yet been demonstrated under DocGo ownership.

What should investors watch next from DocGo?

The key items are revenue per medical transport against the record volume count, the split between organic and acquired growth within the 19% figure, Hicuity's run-rate contribution to revenue and EBITDA net of integration costs, and the balance sheet position after funding the deal, given the share price is below 0.50.

Sources

DocGo Inc (DCGO) (Q2 2026) Earnings Call Highlights: Record Volumes and Strategic Hicuity ... — GuruFocus

Photo: DΛVΞ GΛRCIΛ · Pexels Licence — source